10-K: UFP Technologies Reports Strong 2025 Sales Growth Amid Acquisitions

UFP Technologies, a contract development and manufacturing organization, reported a 19.5% increase in net sales to $602.8 million for 2025, driven by strategic acquisitions and medical market expansion, despite a cybersecurity incident and labor issues.

Summary

• Net sales increased 19.5% to $602.8 million for the year ended December 31, 2025, up from $504.4 million in 2024.
• Sales to customers in the medical market grew 23.2%, primarily due to acquisitions made in 2024 and 2025, which collectively contributed approximately $168.3 million in sales for 2025.
• Organic sales growth was 1.5% for the year ended December 31, 2025.
• Gross profit as a percentage of net sales decreased to 28.3% in 2025 from 29.1% in 2024.
• The AJR Labor Issue resulted in over $6.3 million in incremental labor cost to cost-of-sales for 2025, impacting gross margins.
• Selling, General and Administrative Expenses (SG&A) increased 24.5% to $77.4 million in 2025, representing 12.8% of net sales, up from 12.3% in 2024.
• Net income from consolidated operations was $68.3 million in 2025, compared to $58.981 million in 2024.
• Basic net income per common share was $8.87 in 2025, and diluted net income per share was $8.75.
• Two customers, Intuitive Surgical SARL and Stryker, comprised approximately 24.3% and 21.5%, respectively, of total net sales for 2025.
• A material IT systems incident (Cyber Incident) was detected on February 14, 2026, impacting functions such as billing and label making, with some company data potentially stolen or destroyed. The company believes it has been remediated and does not expect a material financial impact.
• Net cash provided by operating activities was approximately $91.9 million in 2025.
• Net cash used in investing activities was approximately $27.6 million, primarily for capital expenditures and acquisitions.
• Net cash used in financing activities was approximately $58.2 million, mainly due to payments on the revolving line of credit and principal payments of long-term debt.
• Outstanding borrowings under the Third Amended and Restated Credit Agreement were approximately $135.5 million at December 31, 2025, with a weighted average interest rate of 5.1%.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting strong top-line growth driven by strategic acquisitions and medical market expansion, but tempered by operational challenges like declining gross margins, increased SG&A, and the recent cybersecurity incident.

Positives

• Net sales increased significantly by 19.5% to $602.8 million in 2025.
• The medical market, the company's primary focus, experienced strong growth of 23.2% in sales.
• Acquisitions made in 2024 and 2025 contributed substantially to sales growth, adding $168.3 million in 2025.
• Achieved positive organic sales growth of 1.5% in 2025.
• Net income increased to $68.3 million in 2025 from $58.981 million in 2024.
• The effective income tax rate decreased to 17.2% in 2025 from 19.2% in 2024, largely due to a shift in pre-tax income to favorable tax jurisdictions and increased discrete tax benefits.
• Generated strong net cash provided by operating activities of $91.9 million in 2025.
• The company was in compliance with all financial covenants under its Third Amended and Restated Credit Agreement as of December 31, 2025.
• Management believes the February 2026 Cyber Incident is not reasonably likely to materially impact the company's financial condition or results of operations, and expects significant insurance recoveries for direct costs.

Negatives

• Gross profit as a percentage of net sales decreased to 28.3% in 2025 from 29.1% in 2024.
• Overhead and labor costs collectively increased 3.8% as a percentage of net sales in 2025.
• The AJR Labor Issue resulted in over $6.3 million in incremental labor cost to cost-of-sales and decreased productivity in AJR operations during 2025.
• Selling, General and Administrative Expenses (SG&A) increased as a percentage of sales to 12.8% in 2025 from 12.3% in 2024.
• A material IT systems incident (Cyber Incident) was detected in February 2026, which impacted many IT systems and affected functions such as billing and label making for customer deliveries, with certain data appearing to have been stolen or destroyed.
• The contingent consideration for the Welch acquisition has no fair value as of December 31, 2025, as Welch did not achieve its EBITDA targets for 2024 and 2025, and it is not probable for 2026, indicating underperformance relative to initial expectations.
• Net cash used in financing activities was $58.2 million in 2025, primarily due to payments on the revolving line of credit and long-term debt principal payments.

Risks

• Business, operating results, and cash flows may be adversely affected by inflation, potentially impacting manufacturing costs, operating expenses, and customer purchasing power.
• Inability to contain or reduce costs due to substantial price competition and upward pressure on material and labor costs could harm profitability.
• Ongoing geopolitical conflicts (Russia-Ukraine, civil unrest in Haiti, Israel-Hamas War) could disrupt international commerce, supply chains, and operations, particularly in the Dominican Republic where manufacturing facilities are located.
• Dependence on a small number of customers (top two customers represented 45.8% of net sales in 2025) for a large percentage of net sales, with the loss or reduction of sales to any such customer having a material adverse effect.
• Products could contain undetected errors or defects or fail to meet specifications, leading to required enhancements, recalls, negative publicity, or costly litigation.
• New technologies developed by competitors could decrease demand for existing products and result in a loss of market share.
• Failure to comply with specific provisions of customer contracts or Food and Drug Administration (FDA) regulations could result in contract termination, fines, or suspension from future government contracting.
• Increased focus and evolving views on climate change and other ESG issues could lead to more restrictive regulatory standards, compliance requirements, and increased operational costs.
• Physical impacts of climate change could disrupt operations, impact material availability and cost, exacerbate supply chain risks, and increase insurance costs.
• Acquisitions or other strategic relationships involve inherent risks, including difficulty identifying suitable candidates, challenges in integration, diversion of management's attention, and failure to realize anticipated benefits.
• Failure to retain key executive officers and essential sales, engineering, technical, back-office, and management personnel could impair the ability to execute business strategy.
• Operating in highly competitive industries, including from customers bringing programs in-house, could lead to price reductions, reduced margins, and loss of market share.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws (e.g., GDPR, CCPA) may adversely impact business and financial results, leading to fines or litigation.
• Security breaches, including cybersecurity incidents, could compromise information, expose the company to liability, and harm its reputation and business.
• Disruptions in the supply of components and raw materials, especially for certain specialized foams and thermoplastic urethane, could cause production delays or reductions.
• Failure to accurately forecast component and raw material requirements could lead to excess inventory or material shortages, impacting operations and customer relationships.
• Inability to protect proprietary technology from infringement could reduce profit margins and competitive advantage.
• Products could infringe the intellectual property rights of others, leading to costly litigation, substantial damages, or the inability to use essential technology.
• Reductions in the availability of energy supplies or an increase in energy costs may increase operating costs.
• Consolidation in the healthcare industry could result in greater competition and reduce net sales.
• Healthcare industry cost containment and healthcare reform measures could reduce sales of products.
• Expansion of operations into markets outside of the U.S. subjects the company to political, economic, legal, operational, and other risks, including foreign currency fluctuations and compliance with foreign laws.
• Significant tariffs or other restrictions on imports or retaliatory measures by foreign countries could materially harm revenue and results of operations.
• Implementation of artificial intelligence (AI) technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences.
• Changes in foreign currency rates could have a material adverse effect on financial position, results of operations, and cash flows.
• Restrictions in credit facilities may limit business and financial activities, including the ability to obtain additional capital.
• Operating results may fluctuate, making future performance difficult to forecast and potentially leading to stock price volatility.
• A complex tax profile due to global operations may lead to increases and variability in the quarterly and annual effective tax rate.
• The company may never realize the full value of its intangible assets ($338.3 million at December 31, 2025), increasing the risk of large charges to earnings.
• Significant indebtedness ($135.5 million outstanding at December 31, 2025) could adversely affect operations, financial condition, and cash flows.
• Compliance costs or failure to comply with federal, state, and local health and safety laws and regulations could materially adversely affect the business.
• Operations could be disrupted by natural or human causes beyond control, such as natural disasters, accidents, power shortages, or public health issues.

Future Outlook

The company plans to continue its strategy of organic growth and growth through strategic acquisitions. It anticipates adding capacity to enhance operating efficiencies in manufacturing plants and accommodate expected growth in demand. Management believes that existing resources, including the revolving credit facility and cash generated from operations, will be sufficient to fund cash flow requirements, including capital asset acquisitions, through the next twelve months. However, additional capital may be required for future expansion, acquisitions, or other investments, which could be substantial.

Management Comments

• "Our current strategy includes further organic growth and growth through strategic acquisitions."
• "We estimate that the AJR Labor Issue added over $6.3 million in incremental labor cost to our cost-of-sales for year ended December 31, 2025."
• "As of the date hereof, the Cyber Incident has not had a material impact on the Company’s financial systems, operations or financial condition."
• "While the Company’s investigation and assessment of this incident is ongoing, as of the date of this filing, the Company believes its primary IT systems are operational in all material respects and the Company does not believe the incident is reasonably likely to materially impact the Company’s financial condition or results of operations."
• "We believe that our existing resources, including our revolving credit facility, together with cash expected to be generated from operations, will be sufficient to fund our cash flow requirements, including capital asset acquisitions, through the next twelve months."

Industry Context

StockSavvy.ai notes that UFP Technologies operates as a vital contract development and manufacturing organization (CDMO) in the growing global medical device market, specializing in single-use and single-patient devices. The company's strategy of targeting niche segments with specialized materials and engineering expertise, coupled with strategic acquisitions, positions it to capitalize on outsourcing trends among top medical device manufacturers. The industry faces challenges from intense competition, evolving regulatory landscapes (FDA, ESG), and supply chain disruptions, which UFP Technologies addresses through its diversified manufacturing capabilities and focus on high-performance products.

Comparison to Industry Standards

• The company's focus on single-use and single-patient medical devices aligns with a growing trend in the healthcare industry towards infection prevention and minimally invasive procedures, a segment where companies like Medtronic and Johnson & Johnson are also heavily invested.
• The acquisition strategy, exemplified by the purchases of TPI, UNIPEC, AJR Specialty, AJR Custom Foam, Marble, AJR, Welch, and AQF, is a common approach for CDMOs to expand capabilities, geographic reach, and customer base, similar to strategies seen in larger players like Flex or Jabil Healthcare.
• The reported organic sales growth of 1.5% for 2025, while positive, is lower than the overall 19.5% growth driven by acquisitions, suggesting that while the M&A strategy is effective for top-line expansion, core organic growth may require further focus compared to some industry peers experiencing higher internal growth rates in specific high-demand medical device sub-sectors.
• The decrease in gross margin from 29.1% to 28.3% in 2025, partly attributed to the AJR Labor Issue and increased overhead/labor costs, indicates pressure on profitability that is not uncommon in manufacturing sectors facing inflationary pressures and labor market challenges, similar to those reported by other industrial component manufacturers.

Corporate Governance

Legal Proceedings

• Currently a party to a single employee claim, which management believes should not result in final judgments or settlements that would have a material adverse effect on the company’s financial condition or results of operations.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity issuance for acquisitions; volatility in stock price due to fluctuating operating results; impact of credit facility restrictions on financial activities; potential adverse effects from intangible asset impairment.
• Employees: Increased headcount (4,846 full-time, 503 temporary as of Jan 24, 2026); impact of AJR Labor Issue on productivity and workforce turnover; opportunities for career growth, tuition reimbursement, and training; competitive compensation and benefits; commitment to health and safety.
• Customers: Dependence on a small number of customers (top two 45.8% of net sales); risks of product defects, supply chain disruptions, and cybersecurity incidents affecting product delivery and confidence; potential for reduced demand due to healthcare cost containment.
• Suppliers: Dependence on a limited number of suppliers for certain raw materials (cross-linked foam, TPU, technical polyurethane foams); risks of supply delays or interruptions.
• Creditors: Subject to covenants in the Third Amended and Restated Credit Agreement; exposure to increasing interest rates on variable rate debt.

Next Steps

• Continue organic growth and growth through strategic acquisitions.
• Add capacity to enhance operating efficiencies in manufacturing plants.
• Accommodate anticipated growth in demand.
• Evaluate legal and regulatory notifications and filings required as a result of the Cyber Incident.
• Continue investigation into the nature and scope of unauthorized access from the Cyber Incident.
• Consider additional acquisitions of companies, technologies, or products complementary to the business.

Key Dates

Recommendation

The company demonstrates strong top-line growth driven by strategic acquisitions and expansion in the medical market, which are positive indicators. However, the decline in gross margins, increased SG&A as a percentage of sales, and the significant incremental labor costs from the AJR Labor Issue highlight operational challenges. The recent cybersecurity incident, while currently assessed as non-material financially, introduces an element of uncertainty and potential future costs or reputational damage. The high customer concentration also presents a notable risk. Given these mixed signals, a "hold" recommendation is appropriate for a seasoned investor, suggesting observation of how the company addresses operational inefficiencies and manages the aftermath of the cyber incident, while acknowledging its strategic growth trajectory.

Keywords

UFP Technologies, UFPT, Medical Devices, Contract Manufacturing, SEC Filing, 10-K, Financial Results, Acquisitions, Cybersecurity Incident, Gross Margin, Sales Growth, Medical Market, Patient Handling, Thermoforming, Foam Fabrication, Supply Chain, Risk Factors, Earnings, Corporate Governance, Annual Report